Study of S-1 for Metastatic Colorectal Cancer
Author Information
Author(s): Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T
Primary Institution: National Cancer Center Hospital East
Hypothesis
This study set out to evaluate the efficacy and toxicity of S-1 in patients with metastatic colorectal carcinoma.
Conclusion
S-1 shows similar responses to infusional 5-FU plus leucovorin with manageable toxicity.
Supporting Evidence
- Thirty-five percent of eligible patients achieved partial remission.
- The median survival time was 12 months.
- Major adverse reactions included myelosuppressive and gastrointestinal toxicities.
Takeaway
Doctors tested a new medicine called S-1 on people with a type of cancer, and it worked pretty well without making them too sick.
Methodology
S-1 was given orally to patients for 28 days followed by a 14-day rest, with monitoring for efficacy and toxicity.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Patients with measurable metastatic colorectal carcinoma, none had prior chemotherapy except in adjuvant settings.
Statistical Information
Confidence Interval
95% CI: 25–48%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website